Search results
Showing 166 to 180 of 319 results for breast cancer
Awaiting development Reference number: GID-TA11784 Expected publication date: TBC
Discontinued Reference number: GID-TAG410
This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.
Image-guided percutaneous laser ablation for primary and secondary liver tumours (HTG722)
Evidence-based recommendations on image-guided percutaneous laser ablation for primary and secondary liver tumours. This involves heating up liver tissue to destroy tumours.
View recommendations for HTG722Show all sections
Awaiting development Reference number: GID-TA11110 Expected publication date: TBC
Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]
Discontinued Reference number: GID-TA10539
Discontinued Reference number: GID-TAG432
Discontinued Reference number: GID-TA10028
Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy [ID1260]
Discontinued Reference number: GID-TA10309
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1037)
Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected non-small-cell lung cancer in adults.
Show all sections
Discontinued Reference number: GID-TAG390
Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.
Awaiting development Reference number: GID-TA11973 Expected publication date: TBC
NICE has developed a medtech innovation briefing (MIB) on AlignRT for intracranial stereotactic radiosurgery .
Discontinued Reference number: GID-TA10591